These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1354953)

  • 1. Role of iron and oxidant stress in the normal and parkinsonian brain. Proceedings of a symposium. Sarasota, Florida, November 14-17, 1991.
    Ann Neurol; 1992; 32 Suppl():S1-145. PubMed ID: 1354953
    [No Abstract]   [Full Text] [Related]  

  • 2. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.
    Fahn S; Cohen G
    Ann Neurol; 1992 Dec; 32(6):804-12. PubMed ID: 1471873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
    Floor E
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):709-20. PubMed ID: 10875434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental support for the implication of oxidative stress in the genesis of parkinsonian syndromes.
    Fariello RG
    Funct Neurol; 1988; 3(4):407-12. PubMed ID: 3072276
    [No Abstract]   [Full Text] [Related]  

  • 5. Iron in brain function and dysfunction with emphasis on Parkinson's disease.
    Youdim MB; Ben-Shachar D; Riederer P
    Eur Neurol; 1991; 31 Suppl 1():34-40. PubMed ID: 1649757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron as a cause of Parkinson disease - a myth or a well established hypothesis?
    Friedman A; Galazka-Friedman J; Koziorowski D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S212-4. PubMed ID: 20082993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?
    Andersen JK
    Novartis Found Symp; 2001; 235():11-20; discussion 20-5. PubMed ID: 11280021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proceedings from two sessions of the Symposium on Drug Disposition in Man, held in Sarasota, Florida, November 6--11, 1977.
    Drug Metab Rev; 1978; 8(1):1-150. PubMed ID: 31268
    [No Abstract]   [Full Text] [Related]  

  • 9. The relevance of iron in the pathogenesis of Parkinson's disease.
    Sian-Hülsmann J; Mandel S; Youdim MB; Riederer P
    J Neurochem; 2011 Sep; 118(6):939-57. PubMed ID: 21138437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study on the ability of 1,2,3,4-tetrahydropapaveroline to cause oxidative stress: Mechanisms and potential implications in relation to parkinson's disease.
    Soto-Otero R; Sanmartín-Suárez C; Sánchez-Iglesias S; Hermida-Ameijeiras A; Sánchez-Sellero I; Méndez-Alvarez E
    J Biochem Mol Toxicol; 2006; 20(5):209-20. PubMed ID: 17009235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress.
    Thompson K; Menzies S; Muckenthaler M; Torti FM; Wood T; Torti SV; Hentze MW; Beard J; Connor J
    J Neurosci Res; 2003 Jan; 71(1):46-63. PubMed ID: 12478613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron and dopamine: a toxic couple.
    Hare DJ; Double KL
    Brain; 2016 Apr; 139(Pt 4):1026-35. PubMed ID: 26962053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of metals in neurodegenerative diseases.
    Sayre LM; Perry G; Atwood CS; Smith MA
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):731-41. PubMed ID: 10875436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigations of differences in iron oxidation state inside single neurons from substantia nigra of Parkinson's disease and control patients using the micro-XANES technique.
    Chwiej J; Adamek D; Szczerbowska-Boruchowska M; Krygowska-Wajs A; Wojcik S; Falkenberg G; Manka A; Lankosz M
    J Biol Inorg Chem; 2007 Feb; 12(2):204-11. PubMed ID: 17120075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Synuclein expression is modulated at the translational level by iron.
    Febbraro F; Giorgi M; Caldarola S; Loreni F; Romero-Ramos M
    Neuroreport; 2012 Jun; 23(9):576-80. PubMed ID: 22581044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotoxicity and neuroprotection in Parkinson's disease.
    Lange KW; Youdim MB; Riederer P
    J Neural Transm Suppl; 1992; 38():27-44. PubMed ID: 1491247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron in the brain: implications for Parkinson's and Alzheimer's diseases.
    Youdim MB
    Mt Sinai J Med; 1988 Jan; 55(1):97-101. PubMed ID: 3279308
    [No Abstract]   [Full Text] [Related]  

  • 18. The neuropsychiatry of brain iron.
    Sachdev P
    J Neuropsychiatry Clin Neurosci; 1993; 5(1):18-29. PubMed ID: 8094018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual function in glaucoma. Proceedings of a symposium. Sarasota, Florida, May 19, 1987.
    Surv Ophthalmol; 1989 Feb; 33 Suppl():287-330. PubMed ID: 2718095
    [No Abstract]   [Full Text] [Related]  

  • 20. The possible role of iron in the etiopathology of Parkinson's disease.
    Youdim MB; Ben-Shachar D; Riederer P
    Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.